Current stock page

Financial Data

ABVX Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

ABVXAbivax S.A.

Healthcare / Biotechnology

Low Priority

In Line With Peers

BearishEdge 5/10
$87.58−$2.62 (−2.90%)

Latest quote

  • Momentum
    34
  • Value
    —
  • Quality
    35
  • Risk resilience
    37
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-06-302025-12-312025-06-302024-12-312024-06-302023-12-312023-06-302022-12-31
Revenue$0$0$0$0$0$2.33M$2.25M$2.25M
Gross Profit$0$0$0$0$0$2.33M$2.25M$2.25M
Operating Income-$84.11M-$199.56M-$46.5M-$47.2M-$35.33M-$92.46M-$39.54M-$38.8M
Net Income-$117.43M-$287.69M-$48.41M-$52.37M-$38.77M-$95.79M-$51.95M-$40.29M
EPS-$1.47-$2.1-$1.59-$1.5-$0.65-$1.98-$1.45-$1.81
Cash flow statement
8 periods
Metric2026-06-302025-12-312025-06-302024-12-312024-06-302023-12-312023-06-302022-12-31
Operating Cash Flow-$51.99M-$71.28M-$33.34M-$33.28M-$50.42M-$71.16M-$27.6M-$39.82M
Capital Expenditure-$112K$8K-$19K-$44K-$227K-$117K-$149K-$3.89M
Free Cash Flow-$52.1M-$71.28M-$33.36M-$33.32M-$50.65M-$71.28M-$29M-$43.71M
Net Cash Provided By Operating Activities-$51.99M-$71.28M-$33.34M-$33.28M-$50.42M-$71.16M-$27.6M-$39.82M
Balance sheet
8 periods
Metric2026-06-302025-12-312025-06-302024-12-312024-06-302023-12-312023-06-302022-12-31
Total Assets$462.21M$652.05M$119.64M$205.23M$284.49M$327.06M$171.08M$75.54M
Total Debt$1.21M$45.89M$84.57M$97.36M$113.36M$58.04M$34.69M$39.16M
Cash And Cash Equivalents$387.99M$516.47M$60.95M$144.22M$222.32M$251.94M$114.38M$26.95M
Total Liabilities$95.94M$140.81M$167.92M$164.64M$158.02M$131.05M$90.59M$68.36M
Total Stockholders Equity$366.27M$455.01M-$48.28M$40.58M$126.47M$196.01M$80.49M$7.19M
Key financial metrics
8 periods
Metric2026-06-302025-12-312025-06-302024-12-312024-06-302023-12-312023-06-302022-12-31
P/E ratio————————
P/B ratio19.6115.18——————
P/S ratio————————
Debt To Equity00.1—2.40.90.30.435.45
Free Cash Flow Yield-1.72%-1.51%-1.37%—————
Financial ratios
8 periods
Metric2026-06-302025-12-312025-06-302024-12-312024-06-302023-12-312023-06-302022-12-31
P/E ratio————————
P/B ratio19.6115.18——————
P/S ratio————————
Return On Equity-110.61%-73.87%—-224.57%-106.40%-75.37%-114.61%-9.72%
Debt To Equity00.1—2.40.90.30.435.45

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-16.79x
Pb17.2x
EPS Growth Yoy-126.15%
Gross Margin153.15%
Operating Margin11950.42%
ROE-85.88%
ROIC-60.98%
Debt To Equity0
FCF Yield-2.13%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$87.58
Volume698,950
RSI (14)45.5
MACD-1.51
MACD signal-2.29
MACD histogram0.78
ADX (14)19.41
SMA (50)$94.85
SMA (200)$112.57
ATR (14)$3.90
Historical volatility (annualized)46.95%
Volume (20-day average)815,780

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score37/100
Beta1.18
Annual volatility86.44%
Max Drawdown-50.11%
Sharpe Ratio0.24
VaR (95%, 1-day)-5.17%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

ABVX Financial Data FAQ

What is Abivax S.A.'s revenue?

Abivax S.A.'s revenue is one of the core financial data points for ABVX. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Abivax S.A.'s revenue growing?

Revenue growth shows whether Abivax S.A. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is ABVX's EPS?

ABVX's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Abivax S.A.'s net income?

Abivax S.A.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Abivax S.A. generate?

Free cash flow shows how much cash Abivax S.A. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Abivax S.A. have?

Cash and debt help frame ABVX's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.